The role of arginine-nitric oxide pathway in patients with Alzheimer disease
Related Experiment Video
Updated: Jun 27, 2026

Placement of Extracranial Stimulating Electrodes and Measurement of Cerebral Blood Flow and Intracranial Electrical Fields in Anesthetized Mice
Published on: June 2, 2023
Huseyin Vural1, Burcu Sirin, Nigar Yilmaz
1Department of Biochemistry, Faculty of Medicine, Suleyman Demirel University, Isparta, Turkey. vuralh@yahoo.com
Abstract:
There is a reciprocal regulation of arginase and nitric oxide synthase in L-arginine-metabolizing pathways. There are various evidences of the role of nitric oxide in several neuropsychiatric disorders including Alzheimer's disease. However, there is no study that has investigated the role of arginase as an important part of the arginine regulatory system affecting nitric oxide synthase activity in Alzheimer's disease. This study aims to investigate arginase, manganese (a cofactor of arginase), and total nitrite levels (a metabolite of NO) and their relationship to the arginine-NO pathway in patients with Alzheimer's disease. Arginase activities, Mn, and total nitrite levels were measured in plasma from 47 patients with Alzheimer's disease and 43 healthy control subjects. Plasma arginase activities and manganese were found to be significantly lower and total nitrite level higher in patients with Alzheimer's disease compared with controls. Our results suggest that the arginine-NO pathway is involved in the pathogenesis of Alzheimer's disease.
Related Concept Videos
Alzheimer Disease ll: Pathophysiology
Alzheimer's Disease: Treatment
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Nitric Oxide Signaling Pathway
Alzheimer Disease l: Introduction
Role of Neurotransmitters in Memory
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is critical for...
